Antiviral Activity of Low-Molecular-Weight Fluorinated Compounds Against Influenza A (H1N1) Virus
DOI:
https://doi.org/10.15407/microbiolj86.02.051Keywords:
antiviral agents, fluorinated compounds, influenza viruses, molecular dynamicsAbstract
Influenza A virus takes a stable position in annual acute respiratory disease outbreaks during the autumn-winter period. Antiviral drugs for influenza infection help significantly ease the course of the disease and prevent complications, but there is still no drug to which none of the circulating strains would be resistant. Therefore, the search for new effective drugs against influenza A virus is constantly being conducted, in particular among fluorine-containing organic compounds, taking into account the special properties of fluorine. The goal of the study is to investigate the activity of a group of low-molecular-weight fluorinated compounds against the influenza A (H1N1) virus and to determine the potential mechanism of their action using in silico methods. Methods. Five fluorinated compounds designated as 10S-45, 10S-46, 10S-47, 10S-48 and 10S-49 were studied. In vitro experiments were performed using MDCK cell culture, A/FM/1/47 strain of influenza A (H1N1) virus, and oseltamivir phosphate as a reference drug. The cytotoxic effect on cell culture was determined using the MTT test. Antiviral effect was investigated by post-exposure incubation of compound solutions with cells, and visualization of results was performed using crystal violet dye. The possibility of the interaction of compounds with the cap-binding domain (CBD) of the PB2 subunit of the RNA-dependent RNA polymerase (RdRp) of the virus was evaluated using molecular dynamics simulation. Results. It was established that the studied compounds have a moderate cytotoxic effect on MDCK cell culture: the calculated CC50 values are in the range of 471─577 μg/mL for 10S-45, 10S-46, 10S-47 and 10S-48. Substance 10S-49 is almost 2 times less toxic compared to the rest, but it also has no effect on the influenza virus. Compounds 10S-45, 10S-46 and 10S-48 demonstrate antiviral activity in the range of 12─78 % inhibition of viral reproduction with an inverse dose-dependent effect. Substance 10S-47 showed a relatively stable inhibition of viral reproduction in the range of 63─69 % at all tested concentrations, which is similar to the results of the reference drug. According to the results of the selectivity index calculation, compound 10S-48 has the highest value, and 10S-47 has the lowest one, for the rest of the substances, this indicator is acceptable, but low, compared to the reference drug. For in silico studies, all possible spatial forms of the compounds presented as a mixture of diastereoisomers were generated: 4 stereoisomers each for 10S-45 and 10S-46, as well as 3 for 10S-47. According to the results of molecular docking of substances to the active center of CBD, 10S-45 has the lowest calculated affinity, and 10S-47 has the highest. Accordingly, compound 10S-45 showed no tendency to form ordered interactions with CBD. The 10S-47/CBD complex was not characterized by the presence of stable orientational bonds between receptor and ligand, similar to 10S-48/CBD. However, compound 10S-46 showed a generally stable interaction with CBD, albeit with a period of conformational instability. Conclusions. All studied compounds (except for 10S-49) demonstrate an antiviral effect in vitro against the influenza A (H1N1) virus. Based on the results of the in silico analysis of their interactions with CBD PB2, compound 10S-46 is highly likely to be an inhibitor of the cap-binding activity of RdRp.
Downloads
References
Abraham, M. J., Murtola, T., Schulz, R., Páll, Sz., Smith, J. C., Hess, B., & Lindahl, E. (2015). GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX, 1-2, 19-25. https://doi.org/10.1016/j.softx.2015.06.001
Amblard, F., Patel, D., Michailidis, E., Coats, S. J., Kasthuri, M., Biteau, N., Tber, Z., Ehteshami, M., & Schinazi, R. F. (2022). HIV nucleoside reverse transcriptase inhibitors. European journal of medicinal chemistry, 240, 114554. https://doi.org/10.1016/j.ejmech.2022.114554
Cavaliere, A., Probst, K. C., Westwell, A. D., & Slusarczyk, M. (2017). Fluorinated nucleosides as an important class of anticancer and antiviral agents. Future medicinal chemistry, 9(15), 1809–1833. https://doi.org/10.4155/fmc-2017-0095
Delang, L., Abdelnabi, R., & Neyts, J. (2018). Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral research, 153, 85–94. https://doi.org/10.1016/j.antiviral.2018.03.003
Dufrasne F. (2021). Baloxavir Marboxil: An Original New Drug against Influenza. Pharmaceuticals (Basel, Switzerland), 15(1), 28. https://doi.org/10.3390/ph15010028
Eberhardt, J., Santos-Martins, D., Tillack, A. F., & Forli, S. (2021). AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings. Journal of chemical information and modeling, 61(8), 3891–3898. https://doi.org/10.1021/acs.jcim.1c00203
Eggink, D., Bontjer, I., de Taeye, S. W., Langedijk, J. P. M., Berkhout, B., & Sanders, R. W. (2019). HIV-1 anchor inhibitors and membrane fusion inhibitors target distinct but overlapping steps in virus entry. The Journal of biological chemistry, 294(15), 5736–5746. https://doi.org/10.1074/jbc.RA119.007360
Fujiwara, M., Itou, M., & Yokota, T., inventor. (2002). Neuraminidase inhibitors in the treatment of equine influenza virus infection. WO2001097792A3. https://patents.google.com/patent/WO2001097792A2/en
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002). Multidrug resistance in cancer: role of ATP-dependent transporters. Nature reviews. Cancer, 2(1), 48–58. https://doi.org/10.1038/nrc706
Ismail, M. M. F., & Ayoup, M. S. (2022). Review on fluorinated nucleoside/non-nucleoside FDA-approved antiviral drugs. RSC advances, 12(48), 31032–31045. https://doi.org/10.1039/d2ra05370e
Landrum, G. (2016). RDKit: Open-Source Cheminformatics Software. https://www.rdkit.org/
Massari, S., Desantis, J., Nizi, M. G., Cecchetti, V., & Tabarrini, O. (2021). Inhibition of Influenza Virus Polymerase by Interfering with Its Protein-Protein Interactions. ACS infectious diseases, 7(6), 1332–1350. https://doi.org/10.1021/acsinfecdis.0c00552
Meanwell N. A. (2018). Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design. Journal of medicinal chemistry, 61(14), 5822–5880. https://doi.org/10.1021/acs.jmedchem.7b01788
Muller, J. T., & Al Khalili, Y. (2023). Emtricitabine. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/nbk539853/
O'Boyle, N. M., Banck, M., James, C. A., Morley, C., Vandermeersch, T., & Hutchison, G. R. (2011). Open Babel: An open chemical toolbox. Journal of cheminformatics, 3, 33. https://doi.org/10.1186/1758-2946-3-33
Pagadala, N. S., Bhat, R., Kumar D, J., & Landi, A. (2020). Discovery of anti-influenza nucleoside triphosphates targeting the catalytic site of A/PR/8/34/H1N1 polymerase. Medicinal chemistry research: an international journal for rapid communications on design and mechanisms of action of biologically active agents, 29(8), 1463–1477. https://doi.org/10.1007/s00044-020-02561-0
Pekka, M., Lennart, N. (2001). Structure and Dynamics of the TIP3P, SPC, and SPC/E Water Models at 298 K. J Phys Chem A, 105(43), 9954–9960. https://doi.org/10.1021/jp003020w
Schrödinger, L., DeLano, W. (2020). PyMOL. http://www.pymol.org/pymol
Sokol R. (2017). Sofosbuvir/Velpatasvir (Epclusa) for Hepatitis C. American family physician, 95(10), 664–666. https://www.aafp.org/pubs/afp/issues/2017/0515/p664.html
Turner, P. J. (2005). XMGRACE, Version 5.1. 19. Center for Coastal and Land-Margin Research, Oregon Graduate Institute of Science and Technology, Beaverton, OR, 2. https://scholar.google.com/scholar_lookup?title=XMGRACE,+Version+5.1.19&author=PJ+Turner&publication_year=2005&
Vanommeslaeghe, K., Hatcher, E., Acharya, C., Kundu, S., Zhong, S., Shim, J., Darian, E., Guvench, O., Lopes, P., Vorobyov, I., & Mackerell, A. D., Jr (2010). CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. Journal of computational chemistry, 31(4), 671–690. https://doi.org/10.1002/jcc.21367
Wedemeyer, H., Forns, X., Hézode, C., Lee, S. S., Scalori, A., Voulgari, A., Le Pogam, S., Nájera, I., & Thommes, J. A. (2016). Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies. PloS one, 11(1), e0145409. https://doi.org/10.1371/journal.pone.0145409
Wu, X., Wu, X., Sun, Q., Zhang, C., Yang, S., Li, L., & Jia, Z. (2017). Progress of small molecular inhibitors in the development of anti-influenza virus agents. Theranostics, 7(4), 826–845. https://doi.org/10.7150/thno.17071
Zardecki, C., Dutta, S., Goodsell, D. S., Lowe, R., Voigt, M., & Burley, S. K. (2022). PDB-101: Educational resources supporting molecular explorations through biology and medicine. Protein science: a publication of the Protein Society, 31(1), 129–140. https://doi.org/10.1002/pro.4200
Zoete, V., Cuendet, M. A., Grosdidier, A., & Michielin, O. (2011). SwissParam: a fast force field generation tool for small organic molecules. Journal of computational chemistry, 32(11), 2359–2368. https://doi.org/10.1002/jcc.21816
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Mikrobiolohichnyi Zhurnal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
